Patents by Inventor Trivedi MADHAVKUMAR DILIPBHAI

Trivedi MADHAVKUMAR DILIPBHAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral liquid compositions of Enzalutamide and method of manufacturing thereof
    Patent number: 12150930
    Abstract: The present invention relates to oral liquid formulations of Enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. Further, the invention relates to providing an economical and technically advanced dosage form over existing dosage forms. In addition, the present invention also provides an improved process for preparation of Enzalutamide oral liquid formulation. The present invention further provides such compositions for the treatment of for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
    Type: Grant
    Filed: July 31, 2023
    Date of Patent: November 26, 2024
    Assignee: BDR Pharmaceuticals Int'l Pvt. Ltd.
    Inventors: Shah Dharmesh Mahendrabhai, Badiger Aravind Manappa, Sharma Mukeshkumar Subhashchandra, Trivedi Madhavkumar Dilipbhai, Choksi Rakshit Ketanbhai, Vora Pratik Ashwinbhai, Agrawal Vijay Ashok, Gandhi Prashant Kanaiyalal, Panchal Nimitkumar Harishchandra, Mori Nitin Merubhai, Jayaswal Nilay Manikant, Darji Hirenkumar Jitendrakumar
  • NOVEL ORAL LIQUID COMPOSITIONS OF ENZALUTAMIDE AND METHOD OF MANUFACTURING THEREOF
    Publication number: 20240058306
    Abstract: The present invention relates to oral liquid formulations of Enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. Further, the invention relates to providing an economical and technically advanced dosage form over existing dosage forms. In addition, the present invention also provides an improved process for preparation of Enzalutamide oral liquid formulation. The present invention further provides such compositions for the treatment of for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
    Type: Application
    Filed: July 31, 2023
    Publication date: February 22, 2024
    Inventors: Shah Dharmesh Mahendrabhai, Badiger Aravind Manappa, Sharma Mukeshkumar Subhashchandr, Trivedi Madhavkumar Dilipbhai, Choksi Rakshit Ketanbhai, Vora Pratik Ashwinbhai, Agrawal Vijay Ashok, Gandhi Prashant Kanaiyalal, Panchal Nimitkumar Harishchandra, Mori Nitin Merubhai, Jayaswal Nilay Manikant, Darji Hirenkumar Jitendrakumar
  • ORAL FORMULATIONS OF NINTEDANIB AND METHOD OF MANUFACTURING THEREOF
    Publication number: 20230398111
    Abstract: The present invention relates to an oral soft-gelatin capsule dosage form of Nintedanib and pharmaceutically acceptable salt thereof. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form as well as nearest prior-arts. Moreover, the dissolution rate and stability of the patient compliant Nintedanib formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides an oily dispersion without using lecithin is prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.
    Type: Application
    Filed: October 14, 2021
    Publication date: December 14, 2023
    Inventors: Shah Dharmesh MAHENDRABHAI, Badiger Aravind Manappa, Sharma Mukeshkumar SUBHASHCHANDRA, Trivedi Madhavkumar DILIPBHAI, Choksi Rakshit KETANBHAI, Panchal Samirkumar BABULAL, Vora Pratik ASHWINBHAI, Patel Harikrishnabhai VINUBHAI, Shah Shreyash PRAKASHKUMAR, Gandhi Prashant KANAIYALAL
  • ORAL FORMULATIONS OF EDARAVONE AND METHOD OF MANUFACTURING THEREOF
    Publication number: 20220409588
    Abstract: The present invention relates to oral suspension dosage form of Edaravone. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form. Moreover, the solubility and stability of the patient compliant Edaravone formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides a suspension composition prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.
    Type: Application
    Filed: July 17, 2020
    Publication date: December 29, 2022
    Inventors: Shah Dharmesh MAHENDRABHAI, Badiger ARAVIND MANAPPA, Patel BHAVESH NAGINBHAI, Choksi RAKSHIT KENTANBHAI, Patil MAYURKUMAR PURSHOT-TAMBHAI, Shah JIGAR ATULKUMAR, Trivedi MADHAVKUMAR DILIPBHAI